The company's quarterly outperformance was anchored by flagship cancer therapy Keytruda, which delivered $8.60 billion in sales against analyst projections of $7.73 billion. Portfolio diversification also bolstered top-line gains, highlighted by Gardasil vaccine revenues reaching roughly $2 billion alongside a 93% surge from lung treatment Winrevair. Even after absorbing a $400 million charge tied to a licensing partnership with Chinese drugmaker SciBrunch, leadership raised its full-year earnings expectations.
Key points
Uptake of Keytruda Qlex is crucial for migrating patients away from intravenous infusions…: Uptake of Keytruda Qlex is crucial for migrating patients away from intravenous infusions before crucial patent protections lapse in 2028.
Accelerated demand for Winrevair and Gardasil demonstrates expanding revenue streams outs…: Accelerated demand for Winrevair and Gardasil demonstrates expanding revenue streams outside of the central oncology franchise.
Strong underlying margins enabled management to raise full-year profit projections despit…: Strong underlying margins enabled management to raise full-year profit projections despite absorbing a substantial licensing fee for SciBrunch.
Sources checked by our analysis pipeline: 1
Merck on Thursday topped third-quarter estimates and hiked its adjusted profit outlook, as its immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
The pharmaceutical giant now expects adjusted earnings to be between $2.77 and $2.82 per share. That adjusted profit outlook is up from a previous range of $2.66 to $2.76 per share. The guidance now includes a one-time charge of $400 million, or 12 cents per share, related to its licensing agreement with the Chinese cancer drugmaker SciBrunch
Merck also narrowed the low end of its 2026 revenue guidance, now expecting sales between $66.8 billion and $67.3 billion. That compares to a previous outlook of $66.3 billion to $67.3 billion.
The company has been on a deal spree as it races to offset generic competition for Keytruda after key patents begin expiring in 2028.
Merck is also positioning the new form of the drug, Keytruda Qlex, as a cornerstone of its growth strategy. The goal is to transition patients from the original intravenous version to Qlex, considered a more convenient under-the-skin injection. This strategy…
The combined entity will bring together two major players in the on-demand delivery space to consolidate their market presence. This corporate consolidation unites restaurant and grocery fulfillment under a single umbrella to expand overall transaction volume. Stakeholders anticipate significant operational shifts across the delivery sector as the unified platforms scale their shared logistics.
The international technology group experienced a quarterly shortfall in bookings due to the unpredictable timing of large-scale customer projects. This underperformance reflects ongoing volatility in major contract awards across the industrial plant engineering sector. Stakeholders are monitoring how these irregular order patterns will affect the company's backlog and medium-term revenue pipeline.
Financial figures for the industrial group demonstrate stronger business momentum than analysts had projected for the recent three-month period. Demand translated into better-than-anticipated commercial activity across its core metrics. These figures establish a solid footing as the organization navigates market conditions through the remainder of the year.